| PATENT REGISTER | |||||||||||||||||||||||||||||||||||||
| A Supplementary Protection Certificate (SPC) exists for this Patent. To view the SPC Details click following SPC number(s): 2013/013 2014/038 | |||||||||||||||||||||||||||||||||||||
| Status | Expired | Patent No. | 1506211 | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Application No. | 03736643.2 | Date of Filing | 15/05/2003 | ||||||||||||||||||||||||||||||||||
| Date Grant Published | 07/02/2007 | Application Published | 16/02/2005 | ||||||||||||||||||||||||||||||||||
| Title of Invention | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD | ||||||||||||||||||||||||||||||||||||
| Priority |
|
||||||||||||||||||||||||||||||||||||
| Current Proprietor |
AstraZeneca AB SE-151 85, Södertälje SWEDEN |
||||||||||||||||||||||||||||||||||||
| Address for service |
FRKelly Waterways House Grand Canal Quay Dublin D02 PD39 IRELAND |
||||||||||||||||||||||||||||||||||||
| Renewal Fees |
|
||||||||||||||||||||||||||||||||||||
| Publication Language | English | ||||||||||||||||||||||||||||||||||||
| Translation Received Date | |||||||||||||||||||||||||||||||||||||
| 22/02/2007 | Address for Service recorded as F.R. KELLY & CO., 27 Clyde Road, Dublin 4, IE, received on 14/02/2007. | ||||||||||||||||||||||||||||||||||||
| 02/04/2013 | Request for grant a Supplementary Protection Certificate, citing Patent number 1506211 as the relevant basic patent, in respect of the product Dapagliflozin and pharaceutically acceptable salts threof filed on 26/03/2013. Reference number of request is 2013/013. | ||||||||||||||||||||||||||||||||||||
| 20/05/2013 | Supplementary Protection Certificate Number 2013/013, having an expiry date of 11/11/2027 granted on 20/05/2013. | ||||||||||||||||||||||||||||||||||||
| 04/04/2014 | Change of Proprietorship from Bristol-Myers Squibb Company, Route 206 and Province Line Road , P.O. Box 4000, Princeton NJ 08543-4000, United States of America to AstraZeneca AB, Västra Mälarehamnen 9, S-151 85 Södertälje, Sweden, by virtue of Deed of Assignment, dated 01/02/2014. | ||||||||||||||||||||||||||||||||||||
| 28/04/2014 | Change of address of proprietor from AstraZeneca AB, Västra Mälarehamnen 9, S-151 85 Södertälje, Sweden to AstraZeneca AB, SE-151 85, Södertälje, Sweden recorded on 24/04/2014. | ||||||||||||||||||||||||||||||||||||
| 08/07/2014 | Request for grant a Supplementary Protection Certificate, citing Patent number 1506211 as the relevant basic patent, in respect of the product A combination of dapagliflozin or a pharmaceutically acceptable salt thereof and metformin and pharmaceutically salts thereof as a protected by basic patent EP1506211 B1 filed on 07/07/2014. Reference number of request is 2014/038. | ||||||||||||||||||||||||||||||||||||
| 23/02/2017 | The expiry date of SPC No. 2013/013 has been amended to bring it into line with the decision from the Court of Justice of the European Union in Case C-471/14. New expiry date is 13/11/2027. | ||||||||||||||||||||||||||||||||||||
| 21/06/2021 | Request for grant of Supplementary Protection Certification No. 2014/038 rejected in respect of Article 10(2) of Regulation (EC) No. 469/2009 | ||||||||||||||||||||||||||||||||||||
| 05/11/2021 | Appeal against decision of the Controller filed in the High Court on 20 October 2021 [Record No. 2021/184 Sp] | ||||||||||||||||||||||||||||||||||||
| 15/11/2022 | Application for an extension of the duration of Supplementary Protection Certificate No. 2013/013 filed on 14/11/2022. | ||||||||||||||||||||||||||||||||||||
| 06/06/2023 | Patent expired on 14/05/2023. | ||||||||||||||||||||||||||||||||||||
